

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (Use as many sheets as necessary) of

3

Filing Date January 27, 2006 First Named Inventor Michela Rosini Art Unit 1614 Examiner Name 20022/42334 Attorney Docket Number

Complete if Known

10/591.515-Conf. #1673

RU-2 039 733-C1	07-20-1995	Vserossijskij Nauchnyj Tsentro po Bezopasnosti Biologicheski Aktivnykh Veshchestv	Abstract Only
WO-93/14070	07-22-1993	Institut National de la Sante et de la Recherche Medicale	Abstract Only
WO-93/20040	10-14-1993	Eastman Kodak Company	
WO-99/29693	06-17-1999	Minnesota Mining and Manufacturing Company	
WO-00/50391	08-31-2000	Merck & Company, Inc.	
WO-00/53601	09-14-2000	The University of Mississippi	
WO-00/59899	10-12-2000	Societe de Conseil de Recherches et d'Applications Scientifiques	Abstract Only
WO-00/76505	12-21-2000	3M Innovative Properties Company	
WO-01/25226	04-12-2001	Bethesda Pharmaceuticals, Inc.	
WO-02/076177	10-03-2002	Bethesda Pharmaceuticals, Inc.	
WO-03/053366	07-03-2003	OSI Pharmaceuticals, Inc.	
WO-03/087035	10-23-2003	Alma Mater Studiorum	
WO-05/048933	06-02-2005	3M Innovative Properties Company	
WO-05/048945	06-02-2005	3M Innovative Properties Company	
WO-05/123079	12-29-2005	3M Innovative Properties Company	
WO-06/029115	03-16-2006	3M Innovative Properties Company	

Application Number

'EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "CITE NO.: Those application(s) which are marked with an single a settink (?) next to the Cite No. are not supplied (under 37 CFT. 19(6)(2)(iii)) because that application was filled after June 3,003 or as a valuable in the IFW. "Applicant's unique clainton designation number (optional)." See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplg.gov.or/wPEP 901.04">www.usplg.gov.or/wPEP 901.04</a>. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For a panances patent documents, the indication of the year of the Emperor must procode the serial number of the patent document." Kind of document by the apopropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English language Translation is attached."

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
		Akkas, "Molecular Investigation Of Antioxidants On Rat Brain Tissues," Thesis Submitted to the Graduate School of Natural and Applied Sciences of The Middle East Technical University (2003).					
		Bartolini et al., "ß-Amyloid Aggregation Induced By Human Acetylcholinesterase: Inhibition Studies," Biochem. Pharmacol., 65:407-416 (2003).					
		Carlier et al., "Potent, Easily Synthesized Huperzine A-Tacrine Hybrid Acetylcholoinesterase Inhibitors," <i>Bioorg. Med. Chem. Lett.</i> , 9:2335 (1999).					
		Cavallito et al., "Amino-and Ammonium-Alkylaminobenzoquinones as Curarimimetic Agents,"					

Examiner   Signature	Date Considered	

Substitute for form 1449/PTO				Complete if Known		
	Substitute for form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)		Application Number	10/591,515-Conf. #1673		
11	<b>IFORMATIO</b>	N DI	SCLOSURE	Filing Date	January 27, 2006	•
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Michela Rosini	•
				Art Unit	1614	
	(Use as many sl	reets as	necessary)	Examiner Name		
Sheet 3 of 3		Attorney Docket Number	20022/42334			

J. Amer. Chem. Society, 72:2661-2665 (1950).
Cavallito, "Quaternary Ammonium Alkylaminobenzoquinoes," Chem. Abstr., 53:294-295 (1959).
Cutler et al., "Review Of The Next Generation Of Alzheimer's Disease Therapeutics: Cutlellenges For Drug Development," <i>Prog. Neuro-Psychopharmacol, &amp; Biol. Psychiat.</i> , 25:27-57 (2001).
Gardent, "On Some Dihydro-and Tetrahydroisoquinolines Substituted In The 1 Position With Cyclane Or Cyclene Groups," Annales Pharmaceutiques Francaises, 18:381-393 (1960) [(In Italian) "De Quelques Dihydro-et tétrahydro-isoquinoléines substituées en 1 par des groupes cycylaniques ou cycléniques"].
Gurkan et al., "Syntheses of Novel Indole Lipoic Acid Derivatives And Their Antioxidant Effects On Lipid Peroxidation," Arch. Pharm. Chem. Life Sci., 338:67-73 (2005).
Harnett et al., "Novel Lipoic Acid Analogues That Inhibit Nitric Oxides Synthase," Bioorganic & Med. Chem. Ltrs., 12:1439-1442 (2002).
Luo et al., "Ruthenium Tetraamine Chemistry Of Self-Assembled Monolayers on Gold Surfaces: Substitution And Reactivity At The Monolayer Interface," <i>Langmuir</i> , 14:3602-3606, (1998).
Melchiorre et al., "Acetylcholinesterase Noncovalent Inhibitors Based On A Polyamine Backbone For Potential Use Against Alzheimer's Disease," J. Med. Chem., 41:4186-4189 (1998).
Merck Index, Benzoquinonium Chloride, 1137-1138, pp. 185-186.
Pang et al., "Highly Potent, Selective, And Low Cost Bis-Tetrahydroaminacrine Inhibitors Of Acetylcholinesterase," J. Biol. Chem., 271:23646-23649 (1996).
Rosini et al. "Discovery of Multipotent Drugs For The Treatment Of Alzheimer's Disease," Key Lecture:KL10 (2005).
Rosini et al., "Prazosin-Related Compounds, Effect Of Transforming The Piperazinylquinazoline Moiety Into An Aminomethyltetrahydroacridine System On The Affinity For α1-Adrenoreceptors," J. Med. Chem., 46:4895-4903 (2003).
Rosini et al., "Rational Approach To Discover Multipotent Anti-Alzheimer Drugs," J. Med. Chem., 48:360-363 (Published on Internet Web 12/31/2004).
Schweizer et al., "Sulfonyliminoimidazolidines. A new class of Oral Hypoglycemic Agents. 1.1- [[p-[2-(Acylamino)ethylphemy)phemylsulfonyl-2-iminoimidazolidines." J. Med. Chem., American Chemical Society, 26:964-970 (1983).
Shepard et al., "Papaverine Analogs. IV. 1-Cycloaliphatic-6,7-Dimethoxy-Isoquinolines," J. Organic Chem., 19:415-418 (1954).
Stark et al., "New Potent Histamine H3-Receptor Antagonists Of The Amide Type," Eur. J. Pharma. Sci., 3:95-104 (1995).
Stark et al., "Search For Novel Leads for Histamine H-3-Receptor Antagonists: Amine Derivates," Institut für Pharmazie, 52(6):419-423 (1997).
Steinberg et al., "A Hydrophobic Binding Site In Acetylcholinesterase," J. Med. Chem., 18:1056-1061 (1975).
Webb, "Affinity Of Benzoquinonium and Ambenonium Derivatives for the Acetylcholine Receptor, Tested on the Electroplax, and for Acetylcholinesterase in Solution," <i>Biochim. Biophys. Acta</i> , 102:172-184 (1965).

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/591,515-Conf. #1673	
II.	<b>VEORMATION</b>	I DIS	CLOSURE	Filing Date	January 27, 2006	
S	TATEMENT I	BY AI	PPLICANT	First Named Inventor	Michela Rosini	
				Art Unit	1614	
	(Use as many sh	eets as n	ecessary)	Examiner Name		
Sheet	Sheet 1 of 3		Attorney Docket Number	20022/42334		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-2,811,531	10-29-1957	Holly et al.	1		
		US-2,820,799	01-21-1958	Wagner			
		US-2,844,585	07-22-1958	Cavallito			
		US-3,019,227	01-30-1962	Erner			
		US-3,238,224	03-01-1966	O'hara et al.			
		US-3,326,917	06-20-1967	Freimiller et al.			
		US-3,406,199	10-15-1968	Helmut et al.			
		US-3,686,180	08-22-1972	Sutton			
		US-3,936,457	02-03-1976	Schwender et al.			
		US-4,739,064	04-19-1988	Shaw			
		US-5,276,051	01-04-1994	Lesieur et al.			
		US-5,380,920	01-10-1995	Paust et al.			
		US-5,489,694	02-06-1996	Paust et al.			
		US-5,559,113	09-24-1996	Schwartz et al.			
		US-5,670,657	09-23-1997	Kojima et al.			
		US-5,750,560	05-12-1998	Christen et al.			
		US-5,925,668	07-20-1999	Biewenga et al.			
		US-6,090,842	07-18-2000	Packer et al.			
		US-6,111,109	08-29-2000	Denny et al.			
		US-6,204,288	03-20-2001	Pershadsingh et al.			
		US-6,235,772	05-22-2001	Packer et al.			
		US-6,387,945	05-14-2002	Packer et al.			
		US-6,489,336	12-03-2002	Miyamoto et al.			
		US-6,495,690	12-17-2002	Kulkarni et al.			
		US-6,605,637	08-12-2003	Harnett et al.			
		US-6,706,722	03-16-2004	Emig et al.			
		US-6,844,449	01-18-2005				
		US-7,030,251	04-18-2006	Laban et al.			
		US-7,109,362	09-19-2006	Klatt et al.			

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>©</sup>
		EP-0 527 687-A2	02-17-1993	Adir		Abstract Only
		EP-0 869 126-A1	10-07-1998	Sankyo Company Limited		
		EP-1 500 650-A1	01-26-2005	Ishihara Sangyo Kaisha, Limited		
		EP-1 571 146-A1	09-07-2005	Ono Pharmaceutical Company, Limited		
		JP-8-193026	07-30-1996	Teijin Limited		Abstract Only

Examiner	 Date	
Signature	Considered	